Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes

Abstract

BACKGROUND Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clinical response and remission in patients with active ulcerative colitis (UC). The objective of the current study was to determine the effect of tofacitinib on patient-reported outcomes (PROs). METHODS Eligible patients (≥18 years of age… (More)
DOI: 10.1186/s12876-015-0239-9

Topics

7 Figures and Tables

Cite this paper

@inproceedings{Pans2015RandomizedTO, title={Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes}, author={Juli{\'a}n Pan{\'e}s and Chinyu Su and Andrew G. Bushmakin and Joseph C. Cappelleri and Carla M. Mamolo and Paul Healey}, booktitle={BMC gastroenterology}, year={2015} }